Lundbeck reported disappointing data on its anti-psychotic drug, Lu AF35700, in phase III, triggering the largest decline (-27%) in the share price in the company’s history on 25 October 2018. In the first phase III trial, dubbed Daybreak, on 964 patients over ten weeks, Lu AF35700 failed to beat the conventional treatments for treatment-resistant schizophrenia patients.
26 Oct 2018
Schizophrenia drug failure blows up in the face
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Schizophrenia drug failure blows up in the face
Lundbeck reported disappointing data on its anti-psychotic drug, Lu AF35700, in phase III, triggering the largest decline (-27%) in the share price in the company’s history on 25 October 2018. In the first phase III trial, dubbed Daybreak, on 964 patients over ten weeks, Lu AF35700 failed to beat the conventional treatments for treatment-resistant schizophrenia patients.